Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Annexin A1 and leukemia: A systematic review
Abstract
Purpose: To review systematically the involvement of Annexin A1 (ANXA1) in various leukemia cells in order to advance the understanding of ANXA1 role in leukemia.
Methods: The systematic review was carried out via a comprehensive search of electronic databases for all relevant articles published up to September 2017. Specific key words were used to retrieve the articles. All articles were imported into EndNote software while duplicates were removed from the list. The retrieved articles were selected using inclusion and exclusion criteria.
Results: FK228, a novel HDACi and FR235222, increased expression of ANXA1 in Kasumi-1, SKNO-1 and U937 cells, respectively, and induced apoptosis. The study also neutralized ANXA1 in the same cells, which caused a complete blockage of the FK228-induced apoptosis. Resveratrol was reported to markedly increase ANXA1 levels which led to caspase 3-mediated apoptosis on HL-60 cells. Dexamethasone, 17β-estradiol (E2β), all-trans retinoic acid and okadaic acid enhanced ANXA1 mRNA expression in U937, human CCRF-CEM, ATRA-NB4 and HL-60 cell lines. Rp-8-Br-cAMPs prevented dexamethasone-, E2β- and dBcAMP-induced ANXA1 synthesis via the activation of cAMP-respondelement binding protein (CREB). ANXA1 levels were reduced dramatically in K562/ADR cells as compared to K562 cells. When ANXA1 was upregulated by transfection in these cells, the cells exhibited a decrease in resistance to ADR and vincristine.
Conclusion: ANXA1 expression is induced by different drugs which leads to apoptosis in different types of cell. ANXA1 plays a role in the drug resistance of leukemic cells.
